Evaluation and Management of Elevated AST in Infants

1. Pathophysiology and Differential Diagnosis

AST is less liver‑specific than ALT and may be elevated in disorders of the heart, skeletal muscle, kidneys, brain, or red‑blood‑cell pathology. 1
A hepatocellular pattern (AST/ALT ≫ ALP) in infants most commonly reflects viral hepatitis, metabolic disorders, α‑1 antitrypsin deficiency, or Wilson disease. [1][5]
An AST : ALT ratio > 2 should raise suspicion for non‑hepatic sources such as hemolysis or myopathy. 1
A cholestatic pattern (elevated ALP with or without bilirubin rise) suggests biliary obstruction or impaired bilirubin uptake. [1][5]

Hepatosplenomegaly together with failure to thrive is characteristic of lysosomal storage disorders, especially acid sphingomyelinase deficiency (ASMD), which typically presents at 4–6 months with elevated transaminases and progressive deterioration. [2][3]
Conjugated hyperbilirubinemia in infants with prolonged jaundice (1–2 months) indicates α‑1 antitrypsin deficiency in 7–18 % of neonatal cholestasis cases (excluding biliary atresia). 4
Neurologic signs or developmental regression (e.g., hypotonia, poor head control, inability to sit by 10 months) are hallmarks of infantile neurovisceral ASMD, which progresses to liver failure and death by age 2. [2][3]

Obtain a complete liver panel immediately: ALT, AST, alkaline phosphatase, total and direct bilirubin, and GGT. [1][5]
Add coagulation studies (PT/INR) and serum albumin to evaluate hepatic synthetic function. 6
Perform a complete blood count to detect thrombocytopenia or leukopenia that may accompany storage disorders. 3

α‑1 Antitrypsin phenotype – liver dysfunction often first evident at 1–2 months with modest conjugated bilirubin elevation; abnormal levels may persist for years. 4
Viral hepatitis panel (HAV, HBV, HCV serology) plus CMV and EBV testing when indicated. [1][7]
Metabolic screening – if hepatosplenomegaly is present, assay acid sphingomyelinase activity to confirm ASMD. [2][3]
Abdominal ultrasound – assess for hepatosplenomegaly, biliary obstruction, or hepatic steatosis. 5

Repeat liver enzymes in 1–2 weeks to verify persistence. [1][7]
If elevation persists beyond 6 months, proceed with comprehensive serologic and imaging work‑up. 8
Continue clinical monitoring for emergence of symptoms. 7

Accelerate full serologic evaluation and imaging studies. 8
Consider liver biopsy when non‑invasive testing fails to establish a diagnosis. 4
Refer the patient to pediatric gastroenterology or hepatology for specialist management. 7

Early enzyme‑assay testing for ASMD is critical; genotype alone may not differentiate rapidly fatal infantile neurovisceral disease from milder chronic forms. [2][3]
A family history of hepatocellular carcinoma may justify treatment even in the setting of mild liver disease. 9
Eastern European Jewish ancestry is associated with a higher prevalence of founder mutations causing ASMD. [2][3]

α‑1 Antitrypsin deficiency – lifelong follow‑up is recommended; although ~83 % remain clinically healthy throughout childhood, they remain at risk for later complications. 4

Note: Strength of evidence was not explicitly reported in the source material.